New Advances of Cannabinoid Receptors in Health and Disease: 2nd Edition

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 15 February 2025 | Viewed by 1793

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Psychiatry, New York University Langone Medical Center, New York City, NY, USA
2. Scientist, Faculty at Columbia University Medical Center, Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, NY, USA
Interests: endocannabinoids; synaptic plasticity; FASD; AUD; neurodegeneration; learning and memory; epigenetics; gene expression; behavior
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Following a very successful first run, we are pleased to announce the launch of a second edition of a Special Issue on Advances in Cannabinoid Receptors in Health and Disease.

Over the last 30 years, the endocannabinoid system (including cannabinoid receptors) has become an imperative neuromodulatory system, having been shown to play an essential role in health and diseases. Cannabinoid receptors have been implicated in multiple pathophysiological events, ranging from addiction, alcohol abuse and neurodegeneration to memory-related disorders. Significant knowledge has been acquired over the last 25 years. However, much more research is still indispensable to fully appreciate the complex functions of cannabinoid receptors, particularly in vivo, and to unravel their true potential as a source of therapeutic targets.

This Special Issue of Biomolecules aims to present a collection of studies focusing on the most recent advancements in cannabinoid receptor structure, signaling and function in health and disease, including developmental and adult-associated research. Authors are invited to submit cutting-edge reviews, original research articles and meta-analyses of large existing datasets, advancing the field toward a greater understanding of its fundamental and pathophysiological mechanisms. Publication topics include, but are not limited to, studies concerning epidemiology, cancer biology, neuropsychology, neurobehavior, neuropharmacology, epigenetics, genetics and genomics, brain imaging, molecular neurobiology, experimental models and clinical investigations in the format of full-length reviews or original articles. However, other formats reduced in length could also be considered, such as brief reports, short notes, communications or commentaries, as long as the manuscript presents innovative and perceptive content that competently suits the topic of this Special Issue.

Dr. Balapal S. Basavarajappa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegeneration
  • alcohol
  • addiction
  • signaling
  • structure–function

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

30 pages, 1618 KiB  
Review
Unveiling the Potential of Phytocannabinoids: Exploring Marijuana’s Lesser-Known Constituents for Neurological Disorders
by Balapal S. Basavarajappa and Shivakumar Subbanna
Biomolecules 2024, 14(10), 1296; https://doi.org/10.3390/biom14101296 - 13 Oct 2024
Viewed by 1498
Abstract
Cannabis sativa is known for producing over 120 distinct phytocannabinoids, with Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) being the most prominent, primarily in their acidic forms. Beyond Δ9-THC and CBD, a wide array of lesser-known phytocannabinoids, along with [...] Read more.
Cannabis sativa is known for producing over 120 distinct phytocannabinoids, with Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) being the most prominent, primarily in their acidic forms. Beyond Δ9-THC and CBD, a wide array of lesser-known phytocannabinoids, along with terpenes, flavonoids, and alkaloids, demonstrate diverse pharmacological activities, interacting with the endocannabinoid system (eCB) and other biological pathways. These compounds, characterized by phenolic structures and hydroxyl groups, possess lipophilic properties, allowing them to cross the blood–brain barrier (BBB) effectively. Notably, their antioxidant, anti-inflammatory, and neuro-modulatory effects position them as promising agents in treating neurodegenerative disorders. While research has extensively examined the neuropsychiatric and neuroprotective effects of Δ9-THC, other minor phytocannabinoids remain underexplored. Due to the well-established neuroprotective potential of CBD, there is growing interest in the therapeutic benefits of non-psychotropic minor phytocannabinoids (NMPs) in brain disorders. This review highlights the emerging research on these lesser-known compounds and their neuroprotective potential. It offers insights into their therapeutic applications across various major neurological conditions. Full article
Show Figures

Graphical abstract

Back to TopTop